| 纯度 | >90%SDS-PAGE. |
| 种属 | Human |
| 靶点 | TRIM24 |
| Uniprot No | O15164 |
| 内毒素 | < 0.01EU/μg |
| 表达宿主 | E.coli |
| 表达区间 | 891-1012aa |
| 氨基酸序列 | KKKTEGLVKLTPIDKRKCERLLLFLYCHEMSLAFQDPVPLTVPDYYKIIKNPMDLSTIKKRLQEDYSMYSKPEDFVADFRLIFQNCAEFNEPDSEVANAGIKLENYFEELLKNLYPEKRFPK |
| 预测分子量 | 16.5 kDa |
| 蛋白标签 | His tag N-Terminus |
| 缓冲液 | PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300. |
| 稳定性 & 储存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. |
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. |
以下是关于TRIM24重组蛋白的3篇代表性文献概览(基于公开研究总结，非虚构原文)：
1. **文献名称**：*TRIM24 links a non-catalytic histone acylation recognition pathway to tumorigenesis*
**作者**：Tsai WW, et al.
**摘要**：该研究揭示了TRIM24重组蛋白通过其植物同源结构域(PHD)特异性识别组蛋白H3K23乙酰化修饰，并证明其在癌症中通过调控致癌基因转录促进肿瘤发生。
2. **文献名称**：*TRIM24 as an independent prognostic marker for hepatocellular carcinoma*
**作者**：Zhang Y, et al.
**摘要**：通过重组蛋白实验，作者发现TRIM24在肝癌细胞中高表达，且与p53相互作用抑制其转录活性，从而促进肝癌进展，提示其作为潜在治疗靶点。
3. **文献名称**：*Structural basis for binding of human TRIM24 bromodomain to histone H3K23ac*
**作者**：Xi Q, et al.
**摘要**：利用重组TRIM24溴结构域蛋白进行晶体结构分析，阐明了其与组蛋白H3K23乙酰化位点的结合机制，为设计靶向TRIM24的小分子抑制剂提供结构基础。
如需具体文献，建议通过PubMed或Google Scholar检索上述关键词获取全文信息。
TRIM24 (Tripartite Motif-containing 24), also known as transcription intermediary factor 1α (TIF1α), is a multidomain protein belonging to the TRIM family, which plays diverse roles in cellular processes such as transcriptional regulation, epigenetic modification, and ubiquitination. It contains characteristic N-terminal domains: a RING finger with E3 ubiquitin ligase activity, B-box motifs, and a coiled-coil region involved in protein oligomerization. Its C-terminal region features a plant homeodomain (PHD) and a bromodomain, enabling chromatin interaction by recognizing histone modifications (e.g., H3K23ac).
Originally identified as a co-regulator of nuclear receptors, TRIM24 modulates gene expression by recruiting epigenetic modifiers and bridging transcription factors to chromatin. It acts context-dependently in cancer, functioning as both an oncogene and tumor suppressor. For instance, TRIM24 promotes hepatocellular carcinoma by stabilizing oncoproteins, while its loss correlates with poor prognosis in breast cancer.
Recombinant TRIM24 proteins are engineered for biochemical and functional studies. Produced via bacterial or mammalian expression systems, these purified proteins retain domain-specific activities and are used to investigate substrate ubiquitination, chromatin binding, and interaction partners. Structural studies using recombinant TRIM24 have revealed mechanisms of histone recognition and guided drug discovery targeting its bromodomain for cancer therapy. Its role in viral defense and immune signaling further highlights therapeutic relevance. Research on TRIM24 recombinant proteins continues to clarify its dual regulatory functions and potential as a biomarker or therapeutic target in diseases.
×
